ArticleScientific reports2025
Ten year outcomes in three vessel disease treated by CABG versus PCI in an Eastern European registry.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Long-term outcomes in ischemic heart disease are historically underreported in Eastern Europe. Our aim was to report 10-year survival and to identify outcome predictors in patients with three-vessel coronary artery disease (CAD) treated by either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in an Eastern European center. Patients treated for three-vessel CAD with CABG or PCI with drug-eluting stents between August 2013 and February 2025 in a Romanian tertiary hospital were selected for inclusion in this study. All-cause and cardiovascular-cause survival data were available as of May 2025. A total of 7014 patients were included, of which 2759 (39.3%) were treated with CABG and 4255 (60.6%) were treated with PCI. The 10-year all-cause and cardiovascular-cause survival rates were 50.5% and 57.7%, respectively. The CABG group had both higher all-cause and cardiovascular cause mortality than the PCI group (log-rank p = 0.01 and p = 0.03, respectively). CABG was an independent protective predictor, with patients having at least one arterial graft performing better survival than patients having venous grafts only. PCI was an independent predictor of events, with patients undergoing single coronary stenting having better survival than patients undergoing multiple coronary stenting. The 10-year survival after CABG or PCI is lower in Eastern Europe than that reported by other Western registries. However, at the 10-year follow-up, CABG associated with lower incidence of all-cause and cardiovascular-cause death when compared to PCI. These results provide contemporary evidence regarding the long-term benefit of CABG in patients with complex CAD in a real-world scenario.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.